# MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer

> **NCT04729543** · PHASE1,PHASE2 · RECRUITING · sponsor: **Erasmus Medical Center** · enrollment: 20 (estimated)

## Conditions studied

- Melanoma
- Melanoma, Uveal
- Head and Neck Cancer

## Interventions

- **BIOLOGICAL:** Adoptive therapy with autologous MC2 TCR T cells

## Key facts

- **NCT ID:** NCT04729543
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-10-20
- **Primary completion:** 2024-12-20
- **Final completion:** 2027-10-20
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-12-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04729543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04729543, "MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04729543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*